Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
High-dose melphalan (200 mg/m2) as conditioning regimen followed by autologous stem cell transplantation (ASCT) rescue has been established as a standard treatment for patients with multiple myeloma (MM) younger than 65 years of age. However, the role of ASCT in elderly patients older than 65 years...
Main Authors: | , |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956410/ |